Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Rachel Rabinovitch

Concepts (352)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
62
2025
2418
3.740
Why?
Mastectomy, Segmental
29
2025
107
2.050
Why?
Hodgkin Disease
9
2026
173
1.620
Why?
Lymphoma, Large B-Cell, Diffuse
9
2025
195
1.370
Why?
Brachytherapy
10
2019
132
1.260
Why?
Carcinoma, Intraductal, Noninfiltrating
8
2025
61
1.260
Why?
Neoplasm Staging
34
2020
1488
1.040
Why?
Mediastinal Neoplasms
3
2017
54
1.010
Why?
Neoplasm Recurrence, Local
14
2025
1160
1.010
Why?
Mastectomy
8
2025
189
0.990
Why?
Radiotherapy, Adjuvant
18
2025
222
0.980
Why?
Radiotherapy, Conformal
7
2016
75
0.880
Why?
Antineoplastic Combined Chemotherapy Protocols
14
2026
1998
0.880
Why?
Lymphoma, B-Cell
3
2026
150
0.830
Why?
Radiation Pneumonitis
1
2024
31
0.820
Why?
Combined Modality Therapy
25
2024
1271
0.810
Why?
Lymphoma, Follicular
4
2023
57
0.740
Why?
Radiation Oncologists
1
2021
3
0.690
Why?
Medical Oncology
5
2026
345
0.660
Why?
Carcinoma, Ductal, Breast
10
2016
92
0.550
Why?
Radiotherapy Planning, Computer-Assisted
6
2020
150
0.520
Why?
Lymphoma, Mantle-Cell
3
2026
36
0.490
Why?
Female
80
2025
79499
0.480
Why?
Breast
3
2013
155
0.480
Why?
Humans
111
2026
146342
0.470
Why?
Middle Aged
54
2026
36619
0.460
Why?
Mammography
5
2019
175
0.460
Why?
Cord Blood Stem Cell Transplantation
3
2024
103
0.460
Why?
SEER Program
7
2019
233
0.460
Why?
Aged, 80 and over
20
2025
8391
0.440
Why?
Prognosis
16
2024
4351
0.420
Why?
Radiotherapy Dosage
13
2025
289
0.420
Why?
Transplantation Conditioning
5
2024
193
0.410
Why?
Lymph Nodes
5
2016
511
0.400
Why?
Aged
40
2025
26432
0.400
Why?
Breast Neoplasms, Male
1
2013
29
0.400
Why?
Kaplan-Meier Estimate
6
2020
970
0.400
Why?
Neoplasms, Second Primary
3
2020
103
0.390
Why?
Proportional Hazards Models
6
2022
1331
0.390
Why?
BRCA2 Protein
3
2020
69
0.380
Why?
Treatment Outcome
21
2025
11821
0.380
Why?
Adult
46
2026
41087
0.360
Why?
Radiosurgery
2
2019
398
0.360
Why?
Radiotherapy
6
2015
209
0.360
Why?
Prostatic Neoplasms
4
2022
972
0.350
Why?
Lymphoma, Non-Hodgkin
3
2021
124
0.350
Why?
Follow-Up Studies
11
2024
5439
0.350
Why?
Healthcare Disparities
1
2018
733
0.340
Why?
Delivery of Health Care
1
2018
947
0.340
Why?
Survival Analysis
9
2018
1378
0.340
Why?
Mammaplasty
1
2013
150
0.320
Why?
BRCA1 Protein
2
2020
84
0.300
Why?
Whole-Body Irradiation
5
2020
73
0.300
Why?
Lymphoma
2
2025
251
0.300
Why?
Disease-Free Survival
8
2025
778
0.300
Why?
Hematopoietic Stem Cell Transplantation
4
2024
704
0.290
Why?
Anthracyclines
1
2009
49
0.290
Why?
Radiation Oncology
5
2025
83
0.290
Why?
Sentinel Lymph Node Biopsy
3
2008
118
0.280
Why?
Neoplasms, Radiation-Induced
3
2020
100
0.280
Why?
Antibiotics, Antineoplastic
1
2009
141
0.270
Why?
Bile Duct Diseases
1
2008
13
0.270
Why?
Cholestasis, Intrahepatic
1
2008
29
0.260
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2017
78
0.260
Why?
Neoplasm Grading
6
2022
313
0.260
Why?
Bile Ducts, Intrahepatic
1
2008
62
0.260
Why?
Radiotherapy, Intensity-Modulated
3
2014
143
0.260
Why?
Graft vs Host Disease
5
2024
283
0.260
Why?
Thoracic Vertebrae
1
2007
90
0.250
Why?
United States
16
2019
16136
0.240
Why?
Prostheses and Implants
1
2007
137
0.240
Why?
Nutritional Support
1
2006
39
0.230
Why?
Trastuzumab
3
2024
119
0.230
Why?
Heart Diseases
1
2009
343
0.230
Why?
Young Adult
10
2026
14330
0.230
Why?
Orbital Neoplasms
1
2025
28
0.220
Why?
Receptors, Estrogen
4
2016
406
0.210
Why?
Survival Rate
8
2019
2092
0.210
Why?
Transplantation, Haploidentical
1
2024
23
0.210
Why?
Male
28
2025
73396
0.200
Why?
Adolescent
12
2026
22557
0.180
Why?
Time Factors
5
2018
7109
0.180
Why?
Head and Neck Neoplasms
2
2010
563
0.180
Why?
Flutamide
2
2018
7
0.170
Why?
Analysis of Variance
2
2015
1298
0.170
Why?
Goserelin
2
2018
8
0.170
Why?
Neoplasm Invasiveness
4
2019
504
0.170
Why?
Neoadjuvant Therapy
3
2025
475
0.170
Why?
Patient Care Planning
2
2021
170
0.170
Why?
Cause of Death
2
2016
456
0.160
Why?
Carcinoma, Squamous Cell
1
2006
628
0.160
Why?
Bone Neoplasms
2
2018
272
0.160
Why?
Androgen Antagonists
2
2022
91
0.160
Why?
Survivorship
1
2021
62
0.160
Why?
Deoxycytidine
1
2022
219
0.160
Why?
Tumor Burden
4
2016
326
0.160
Why?
Adenocarcinoma
2
2018
927
0.160
Why?
Azacitidine
1
2021
168
0.160
Why?
Immunoconjugates
1
2021
138
0.150
Why?
Surgical Instruments
1
2000
51
0.150
Why?
Antineoplastic Agents, Immunological
2
2019
200
0.150
Why?
Clinical Trials as Topic
5
2017
1064
0.150
Why?
Retrospective Studies
12
2025
17438
0.150
Why?
Antineoplastic Agents
7
2017
2219
0.150
Why?
Radiation Injuries
3
2016
149
0.150
Why?
Antibodies, Monoclonal, Humanized
2
2017
992
0.150
Why?
Biomarkers, Tumor
2
2024
1339
0.150
Why?
Patient Satisfaction
2
2013
706
0.140
Why?
Vidarabine
3
2018
32
0.140
Why?
Leuprolide
1
2018
21
0.140
Why?
Thiotepa
1
2018
21
0.140
Why?
Public Health Surveillance
1
2018
84
0.140
Why?
Aquaporin 4
1
2019
101
0.140
Why?
Neoplasms
2
2011
2954
0.140
Why?
Necrosis
1
2019
243
0.130
Why?
Diphosphonates
1
2018
68
0.130
Why?
Rituximab
2
2016
208
0.130
Why?
Randomized Controlled Trials as Topic
8
2022
1763
0.130
Why?
Patient Care Management
1
2017
54
0.130
Why?
Imidazoles
1
2018
245
0.120
Why?
Leukemia, Myeloid, Acute
2
2021
702
0.120
Why?
Disease Management
2
2018
651
0.120
Why?
Chemoradiotherapy
1
2018
238
0.120
Why?
Lymphoma, Extranodal NK-T-Cell
1
2016
11
0.120
Why?
Aromatase Inhibitors
1
2017
81
0.120
Why?
Unilateral Breast Neoplasms
1
2016
4
0.120
Why?
Practice Guidelines as Topic
4
2017
1591
0.120
Why?
Multivariate Analysis
3
2009
1543
0.120
Why?
Lymphoma, T-Cell, Peripheral
1
2016
19
0.120
Why?
Margins of Excision
1
2016
55
0.120
Why?
Recurrence
5
2018
1133
0.120
Why?
Datasets as Topic
1
2016
120
0.110
Why?
Esthetics
2
2013
49
0.110
Why?
Chemotherapy, Adjuvant
6
2017
429
0.110
Why?
Biopsy
5
2022
1075
0.110
Why?
Programmed Cell Death 1 Receptor
1
2017
268
0.110
Why?
Risk Reduction Behavior
1
2016
220
0.110
Why?
Gastrointestinal Neoplasms
2
2012
74
0.110
Why?
Prostate-Specific Antigen
3
2022
162
0.110
Why?
Risk Factors
5
2022
10921
0.100
Why?
Carcinoma
1
2016
225
0.100
Why?
Patient Selection
4
2016
728
0.100
Why?
Quality of Life
2
2025
3200
0.100
Why?
Gene Expression Profiling
3
2017
1792
0.100
Why?
Receptors, Progesterone
2
2013
242
0.100
Why?
Insurance Coverage
1
2016
248
0.100
Why?
Antibodies, Monoclonal, Murine-Derived
1
2014
96
0.100
Why?
Cancer Survivors
1
2019
348
0.100
Why?
Societies, Medical
4
2016
907
0.100
Why?
Propensity Score
1
2016
376
0.100
Why?
Genetic Predisposition to Disease
2
2020
2488
0.100
Why?
Beauty
1
2013
19
0.100
Why?
Immunotherapy, Adoptive
3
2023
356
0.100
Why?
Lymphatic Irradiation
2
2010
11
0.100
Why?
Triple Negative Breast Neoplasms
1
2016
220
0.100
Why?
Practice Patterns, Physicians'
3
2017
1408
0.100
Why?
Diagnostic Self Evaluation
1
2013
24
0.100
Why?
Axilla
3
2007
51
0.100
Why?
Confidence Intervals
1
2013
329
0.090
Why?
Gene Expression Regulation, Neoplastic
1
2019
1432
0.090
Why?
Age Distribution
1
2013
399
0.090
Why?
Sex Distribution
1
2013
382
0.090
Why?
Lymphatic Metastasis
4
2019
335
0.090
Why?
Prospective Studies
8
2022
8123
0.090
Why?
Palliative Care
2
2018
1032
0.090
Why?
Carcinoma, Renal Cell
1
1994
231
0.080
Why?
Cyclophosphamide
2
2009
275
0.080
Why?
Immunotherapy
1
2016
671
0.080
Why?
Health Physics
1
2010
7
0.080
Why?
Guideline Adherence
2
2017
594
0.080
Why?
Immunosuppressive Agents
3
2006
829
0.080
Why?
Four-Dimensional Computed Tomography
1
2010
38
0.080
Why?
Lung Neoplasms
2
2018
2675
0.080
Why?
Boronic Acids
1
2010
37
0.080
Why?
Antibodies, Monoclonal
1
2017
1512
0.080
Why?
Clinical Trials, Phase III as Topic
2
2010
116
0.070
Why?
Kidney Neoplasms
1
1994
419
0.070
Why?
Doxorubicin
2
2009
416
0.070
Why?
Pyrazines
1
2010
94
0.070
Why?
Pregnancy Complications, Neoplastic
1
2009
64
0.070
Why?
Thrombophilia
1
2009
89
0.070
Why?
Mutation
1
2020
4093
0.070
Why?
Databases as Topic
1
2008
70
0.070
Why?
Iridium Radioisotopes
1
2007
4
0.070
Why?
Movement
1
2010
290
0.070
Why?
Diagnostic Imaging
1
2010
340
0.070
Why?
Positron-Emission Tomography
3
2017
343
0.060
Why?
Sex Factors
1
2013
2107
0.060
Why?
Antineoplastic Agents, Hormonal
2
2008
196
0.060
Why?
Prednisone
1
2008
229
0.060
Why?
Comorbidity
3
2017
1665
0.060
Why?
Registries
1
2016
2400
0.060
Why?
Syndrome
1
2008
380
0.060
Why?
Fatigue
2
2025
363
0.060
Why?
Incidence
1
2013
2936
0.060
Why?
Sternum
1
2006
26
0.060
Why?
Stomatitis
1
2006
15
0.060
Why?
Age Factors
2
2017
3347
0.060
Why?
Radiology
1
2008
175
0.060
Why?
Carcinoma, Small Cell
1
2006
172
0.060
Why?
Risk Assessment
2
2025
3712
0.060
Why?
Mycophenolic Acid
1
2006
117
0.060
Why?
Conjunctival Neoplasms
1
2025
9
0.060
Why?
Carcinoma, Ductal
1
2005
10
0.060
Why?
Lymphoma, B-Cell, Marginal Zone
1
2025
21
0.050
Why?
Nomograms
1
2025
59
0.050
Why?
Child
3
2024
22693
0.050
Why?
Tacrolimus
1
2006
192
0.050
Why?
Stem Cell Transplantation
1
2006
190
0.050
Why?
Living Donors
1
2006
216
0.050
Why?
Mastectomy, Modified Radical
2
2000
6
0.050
Why?
Anemia, Sideroblastic
1
2003
4
0.050
Why?
Radiography
2
2010
861
0.050
Why?
Reproducibility of Results
5
2012
3416
0.050
Why?
Tomography, X-Ray Computed
3
2009
2786
0.050
Why?
Drug Administration Schedule
2
2018
790
0.050
Why?
Drug Resistance, Neoplasm
2
2019
893
0.050
Why?
Magnetic Resonance Imaging
3
2019
3926
0.040
Why?
Mass Screening
1
2010
1307
0.040
Why?
Lymph Node Excision
3
2009
174
0.040
Why?
Professional Staff Committees
1
2001
11
0.040
Why?
Referral and Consultation
1
2007
881
0.040
Why?
Allografts
1
2021
151
0.040
Why?
Organ Size
2
2013
465
0.040
Why?
Antigens, CD19
1
2021
137
0.040
Why?
Weight Loss
1
2006
858
0.040
Why?
Automation
1
2020
104
0.040
Why?
Protein Kinase Inhibitors
1
2026
983
0.040
Why?
Risk Management
1
2020
81
0.040
Why?
Carcinoma, Lobular
1
2000
59
0.040
Why?
Quality Assurance, Health Care
2
2012
349
0.040
Why?
Respiration
2
2010
208
0.040
Why?
Germ-Line Mutation
1
2020
180
0.040
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2021
292
0.040
Why?
Salvage Therapy
1
2000
166
0.040
Why?
Kallikreins
1
2018
25
0.040
Why?
Workflow
1
2020
182
0.030
Why?
Myeloablative Agonists
1
2018
23
0.030
Why?
Fetal Blood
1
2020
325
0.030
Why?
Maximum Tolerated Dose
2
2010
217
0.030
Why?
Osteoblasts
1
2018
145
0.030
Why?
Radiopharmaceuticals
1
2018
210
0.030
Why?
Sulfonamides
1
2021
594
0.030
Why?
Aftercare
1
2019
225
0.030
Why?
Neutropenia
2
2010
153
0.030
Why?
Genomics
1
2022
853
0.030
Why?
Canada
1
2018
432
0.030
Why?
Retreatment
1
2017
79
0.030
Why?
Asparaginase
1
2016
34
0.030
Why?
Fat Necrosis
1
2016
12
0.030
Why?
Metaplasia
1
2016
54
0.030
Why?
Socioeconomic Factors
2
2017
1327
0.030
Why?
Safety
1
2018
347
0.030
Why?
Ultrasonography
1
2000
788
0.030
Why?
North America
1
2016
300
0.030
Why?
Herpesvirus 4, Human
1
2016
172
0.030
Why?
Europe
1
2016
421
0.030
Why?
Heart
2
2010
626
0.030
Why?
Survivors
1
2019
526
0.030
Why?
Genetic Variation
1
2020
996
0.030
Why?
T-Lymphocytes
1
2023
2012
0.030
Why?
Gene Rearrangement
1
2016
156
0.030
Why?
Postmenopause
2
2009
394
0.030
Why?
Immunophenotyping
1
2016
324
0.030
Why?
DNA, Viral
1
2016
354
0.030
Why?
Advisory Committees
1
2016
228
0.030
Why?
Catheterization, Peripheral
1
2016
116
0.030
Why?
Proto-Oncogene Proteins c-bcl-2
1
2016
237
0.030
Why?
Proto-Oncogene Proteins c-myc
1
2016
157
0.030
Why?
Radioimmunotherapy
1
2014
25
0.030
Why?
Odds Ratio
1
2017
1077
0.030
Why?
Actuarial Analysis
1
1994
15
0.030
Why?
Molecular Targeted Therapy
1
2017
447
0.020
Why?
Clinical Decision-Making
1
2017
365
0.020
Why?
Treatment Failure
1
1994
361
0.020
Why?
Child, Preschool
1
2008
11913
0.020
Why?
Mass Media
1
2012
36
0.020
Why?
Surveys and Questionnaires
1
2025
6073
0.020
Why?
Palpation
1
2010
15
0.020
Why?
Ultrasonography, Mammary
1
2010
17
0.020
Why?
Anti-Bacterial Agents
1
2001
1942
0.020
Why?
Logistic Models
1
2016
2126
0.020
Why?
Urologic Neoplasms
1
2010
31
0.020
Why?
Thoracic Neoplasms
1
2010
40
0.020
Why?
Bortezomib
1
2010
54
0.020
Why?
Lymphopenia
1
2010
62
0.020
Why?
Subcutaneous Fat
1
2010
80
0.020
Why?
Brain Neoplasms
1
2019
1325
0.020
Why?
Nausea
1
2010
111
0.020
Why?
Soft Tissue Neoplasms
1
2010
133
0.020
Why?
Statistics, Nonparametric
1
2010
426
0.020
Why?
Pregnancy Trimester, Second
1
2009
91
0.020
Why?
Genital Neoplasms, Female
1
2010
100
0.020
Why?
Radiation Dosage
1
2010
193
0.020
Why?
Prevalence
1
2016
2861
0.020
Why?
Pregnancy Trimester, First
1
2009
140
0.020
Why?
Calcinosis
1
2010
231
0.020
Why?
Infusions, Intravenous
1
2010
432
0.020
Why?
Diarrhea
1
2010
190
0.020
Why?
Apoptosis Regulatory Proteins
1
2009
186
0.020
Why?
Premenopause
1
2009
130
0.020
Why?
Longitudinal Studies
1
2016
3017
0.020
Why?
Observer Variation
1
2009
356
0.020
Why?
Perimenopause
1
2008
69
0.020
Why?
Credentialing
1
2007
21
0.020
Why?
Quality Control
1
2008
163
0.020
Why?
Fibrosis
1
2010
568
0.020
Why?
In Situ Hybridization, Fluorescence
1
2008
334
0.020
Why?
Algorithms
1
2015
1849
0.020
Why?
Evidence-Based Medicine
1
2010
731
0.020
Why?
Benchmarking
1
2007
193
0.010
Why?
Diagnosis, Differential
1
2010
1503
0.010
Why?
Medicare
1
2012
920
0.010
Why?
Lung
2
2010
4122
0.010
Why?
Taxoids
1
2006
115
0.010
Why?
Etoposide
1
2006
169
0.010
Why?
Carboplatin
1
2006
168
0.010
Why?
Dose-Response Relationship, Drug
1
2010
2022
0.010
Why?
Signal Transduction
1
2019
5246
0.010
Why?
Genital Diseases, Male
1
1985
14
0.010
Why?
Colorado
2
2010
4595
0.010
Why?
Genital Diseases, Female
1
1985
31
0.010
Why?
Chlamydia trachomatis
1
1985
49
0.010
Why?
Biomarkers
1
2016
4340
0.010
Why?
Pharynx
1
1985
60
0.010
Why?
Siblings
1
2006
202
0.010
Why?
Immunohistochemistry
1
2008
1712
0.010
Why?
Neoplasm Proteins
1
2007
444
0.010
Why?
Cisplatin
1
2006
347
0.010
Why?
Rectum
1
1985
180
0.010
Why?
Hematologic Neoplasms
1
2006
170
0.010
Why?
Antilymphocyte Serum
1
2003
55
0.010
Why?
Sexually Transmitted Diseases
1
1985
163
0.010
Why?
Feasibility Studies
1
2007
1135
0.010
Why?
Fatal Outcome
1
2003
302
0.010
Why?
Graft Rejection
1
2006
516
0.010
Why?
Transplantation, Homologous
1
2003
416
0.010
Why?
Skin Neoplasms
1
2009
806
0.010
Why?
Transplantation, Heterologous
1
2001
165
0.010
Why?
Organizational Objectives
1
2001
67
0.010
Why?
Hospitals, Private
1
1999
12
0.010
Why?
Hospitals, County
1
1999
11
0.010
Why?
Hospitals, University
1
1999
178
0.010
Why?
Forecasting
1
2001
388
0.010
Why?
Infant, Newborn
1
2009
6460
0.010
Why?
Reoperation
1
2000
645
0.010
Why?
Pregnancy
1
2009
7230
0.010
Why?
Patient Education as Topic
1
1999
770
0.010
Why?
Bacteriological Techniques
1
1985
66
0.000
Why?
Chlamydia Infections
1
1985
79
0.000
Why?
Risk
1
1985
920
0.000
Why?
Sexual Behavior
1
1985
490
0.000
Why?
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)